- Home
- INKT vs JMM Comparison
INKT vs JMM Comparison
Compare INKT & JMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INKT | JMM |
|---|---|---|
| Founded | 2017 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 54.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | INKT | JMM |
|---|---|---|
| Price | $11.98 | $5.75 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 6.9K | ★ 8.1K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.44% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.48 | $5.67 |
| 52 Week High | $16.80 | $6.52 |
Technical Indicators
Market Signals| Indicator | INKT | JMM |
|---|---|---|
| Relative Strength Index (RSI) | 59.51 | 44.55 |
| Support Level | $10.76 | $5.70 |
| Resistance Level | $12.20 | $5.87 |
| Average True Range (ATR) | 0.69 | 0.05 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 98.89 | 30.77 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.